Navigation Links
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced clinical trial results related to Halozyme's clinical stage drug, pegylated rHuPH20 (PEGPH20). The results were presented at the 2011 EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer", taking place October 27-29 in Brussels, Belgium.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Today's presentation focused on translational biomarker and pharmacodynamic results from the two Phase 1 dose-finding studies in patients with advanced solid tumors that were unresponsive to prior therapies. Study 101 investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, and Study 102 investigated multiple-dosing of PEGPH20 in combination with dexamethasone.  

Results

The pharmacodynamics of PEGPH20 were first evaluated by measuring the concentration of circulating hyaluronan (HA) catabolites. HA plasma levels increased, in a dose-dependent manner, after PEGPH20 administration. Freeing up of HA by PEGPH20 is consistent with the expected mechanism of PEGPH20.

Tumor imaging from subsets of patients pre- and post-administration of PEGPH20 demonstrated that PEGPH20 treatment rapidly restored tumor perfusion and decreased metabolic activity in tumors. Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) showed that the imaging agent was able to access a pancreatic tumor more easily post-administration of PEGPH20. [18F]-fluorodeoxyglucose positron emission tomogra
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
2. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
3. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
4. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
7. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
8. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
9. Halozyme Receives $5.5 Million Payment From Baxter
10. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
11. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... 5 Alba Therapeutics Corporation today,announced that its ... preservation of endogenous insulin production capacity in new-onset,type ... day deliberation period,by the U.S. Food and Drug ... diabetes study in 2008 while focusing the majority,of ...
... Sept. 5 /PRNewswire/ - GenoLogics, a ... software solutions for life sciences research,announced ... Affymetrix,GeneChip-compatible(TM) Applications Program, and its Geneus ... Affymetrix, Inc. (Nasdaq:,AFFX) GeneChip(R) microarray platform. ...
... Fisher,Scientific Inc. (NYSE: TMO ), the world ... business of Davis Inotek Instruments, LLC.,The acquired business ... calibration services. Davis Instruments is a leading provider ... in a,wide range of industries through its extensive ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2GenoLogics' Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform 2GenoLogics' Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4
(Date:4/15/2014)... 16, 2014)A new study from the Women,s Health Initiative ... and menopause symptoms. The study was published online today ... American Menopause Society., The authors analyzed the relationship between ... of menopause symptoms, including hot flashes, night sweats, sleep ... in the calcium and vitamin D WHI trial. , ...
(Date:4/15/2014)... Miami could know as early as 2020 how high ... to a team of researchers including Florida International University ... the National Science Foundation,s (NSF) Florida Coastal Everglades Long-Term ... LTER sites in ecosystems from coral reefs to deserts, ... conclude that sea level rise is one of the ...
(Date:4/15/2014)... If an insect drew a line as it ... a tangled mess. But there,s method to that mess, ... engineering and physics, who tries to find simple physical ... https://cornell.box.com/tbeetle , It turns out the tiger beetle, ... reorientation dance as it chases its prey at blinding ...
Breaking Biology News(10 mins):Low Vitamin D may not be a culprit in menopause symptoms 2Long-term predictions for Miami sea level rise could be available relatively soon 2Photo: Tiger beetle's chase highlights mechanical law 2
... radio, amateur astronomy, and early computing? Well, now ... people from around the world belong to the Do-It-Yourself ... cells, low-cost lab equipment, environmental surveillance, personal bio-monitoring, to ... at the Woodrow Wilson Center is partnering with DIYbio.org, ...
... - A Purdue University researcher has found a sort of ... by about a week. Avtar Handa, a professor of ... a compound that slows aging and delays microbial decay in ... version of The Plant Journal , likely would transfer ...
... URBANA Wet conditions have Illinois pumpkin growers on the ... fields. This disease nearly destroyed the pumpkin industry in 1999, ... the state. While it,s not a new disease to this ... up in Illinois. Mohammad Babadoost, University of Illinois Extension ...
Cached Biology News:Gene leads to longer shelf life for tomatoes, possibly other fruits 2Illinois pumpkin fields face cunning opponent 2
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: